Pathological complete response (pCR) has been shown to predict long-term outcomes in breast cancer patients undergoing primary systemic therapy in aggressive early breast cancer.
Herein we discuss the caveats of determining pCR, and data needed to tailor breast cancer radiation after pCR.
